12 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 15 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 12, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. Baxdrostat, Placebo - Primary Hyperaldosteronism | Phase 3 | Active not recruiting | AstraZeneca | 212 | 2025-08-07 | 2026-10-16 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Relacorilant, Placebo - Hypercortisolism | Phase 3 | Completed | Corcept Therapeutics | 137 | 2020-07-27 | 2025-09-04 |
| 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism | Phase 2 / Phase 3 | Completed | Changi General Hospital | 97 | 2019-12-30 | 2026-10-26 |
| Open-label Treatment in Cushing's Syndrome Levoketoconazole - Cushing Syndrome, Cushing Disease | Phase 3 | Completed | Cortendo AB | 51 | 2019-01-07 | 2025-06-19 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| Adrenal Artery Ablation for Primary Aldosteronism Endovascular chemical Ablation of Adrenal Gland, Sequenced antihypertensvie drugs with titrated dosage - Primary Aldosteronism, Hypertension | Phase 3 | Unknown | Third Military Medical University | 40 | 2018-07-01 | 2018-08-31 |
| Adrenal Artery Ablation Treats Primary Aldosteronism Endovascular chemical Ablation of Adrenal Gland - Primary Aldosteronism, Hypertension | Phase 3 | Completed | Third Military Medical University | 66 | 2017-10-01 | 2019-07-08 |
| A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. Levoketoconazole, Placebo - Endogenous Cushing's Syndrome | Phase 3 | Completed | Cortendo AB | 84 | 2017-09-26 | 2022-11-08 |
| Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome metyrapone - Cushing's Syndrome | Phase 3 | Completed | HRA Pharma | 50 | 2015-04-01 | 2020-09-25 |
| Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease osilodrostat, LCI699 matching placebo - Cushings Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 137 | 2014-10-06 | 2021-01-06 |
| Mifepristone in Children With Refractory Cushing's Disease mifepristone - Cushing's Disease | Phase 3 | Withdrawn | Corcept Therapeutics | 2013-08-01 | 2014-08-04 | |
| Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Mifepristone - Cushing's Disease, Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 4 | 2010-11-01 | 2014-03-18 |
| SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Ct-scan or adrenal vein sampling - Hyperaldosteronism | Phase 3 | Completed | Radboud University Medical Center | 200 | 2010-07-01 | 2015-07-16 |
| An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome mifepristone - Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 30 | 2009-07-01 | 2014-04-02 |
| A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome mifepristone - Cushing's Syndrome | Phase 3 | Completed | Corcept Therapeutics | 50 | 2007-12-01 | 2013-08-22 |
Cushing Syndrome (9) · Pituitary ACTH Hypersecretion (6) · ACTH Syndrome, Ectopic (5) · Hyperaldosteronism (5) · Hypertension (4) · Pituitary Diseases (3) · Adrenal Cortex Neoplasms (2) · Choristoma (2) · Diabetes Mellitus, Type 2 (2) · Hirsutism (2) · Adrenal Gland Neoplasms (1) · Adrenocortical Adenoma (1) · Neoplasm Metastasis (1)
Adrenal Gland Diseases (15) · Endocrine System Diseases (15) · Neoplasms (7) · Brain Diseases (6) · Central Nervous System Diseases (6) · Hyperpituitarism (6) · Hypothalamic Diseases (6) · Nervous System Diseases (6) · Paraneoplastic Endocrine Syndromes (5) · Paraneoplastic Syndromes (5) · Cardiovascular Diseases (4) · Endocrine Gland Neoplasms (4) · Neoplasms by Site (4) · Vascular Diseases (4)
Mifepristone (4) · Corlux (3) · relacorilant (2) · Metyrapone (1) · Osilodrostat (1)
Corcept Therapeutics (6) · Cortendo AB (2) · Third Military Medical University (2) · AstraZeneca (1) · Changi General Hospital (1) · HRA Pharma (1) · Novartis Pharmaceuticals (1) · Radboud University Medical Center (1)
United States (10) · Italy (7) · Spain (7) · Bulgaria (5) · Germany (5) · Netherlands (5) · Poland (5) · Romania (5) · China (4) · France (4) · Israel (4) · Austria (3) · Canada (3) · Hungary (3) · Greece (2)
Andreas Moraitis, MD (2) · Coleman Gross (1) · Coleman Gross, M.D. (1) · Coleman Gross, MD (1) · Fredric Cohen, MD (1) · Jacob Deinum, Dr. (1) · Xavier Valencia, MD (1)
PMID 25013998, PMID 26507877, PMID 22466348, PMID 23970725, PMID 27325147, PMID 29099925, PMID 32730798, PMID 33074401, PMID 34059026, PMID 35058882, PMID 37680892, PMID 38696122, PMID 39610378, PMID 41052284, PMID 41730814